The U.S. Food and Drug Administration formally announced Thursday that it is investigating a serious risk of malignancy linked to both of Novartis's approved gene therapies for spinal muscular atrophy — Zolgensma and Itvisma — after molecular analysis of tumor tissue in Zolgensma patients confirmed a specific causal mechanism: the therapy's viral vector DNA integrating into the genome near a known cancer-driving gene called GLI1 and switching it on.
The FDA's action, published November 6 by its Center for Biologics Evaluation and Research (CBER), marks the first time a U.S. regulator has formally characterized a commercial AAV gene therapy as having caused insertional oncogenesis in humans — moving the risk from "theoretical," the language still on Zolgensma's product label, to confirmed and under active investigation.